Gain Therapeutics, Inc.
GANX
NASDAQ·Healthcare·Biotechnology·Mkt cap $76.8M
$1.80
▼ -1.10%
P/E
-3.60
Mkt Cap
$76.8M
52-Wk Range
$1.53–$4.34
52-Week Range
$1.53 - $4.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 2.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary SDEET platform technology
- Allosteric site targeting mechanism
- Focused pipeline in underserved rare disease markets
- Experienced biotechnology management team
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Clinical trial advancement and regulatory approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+6.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GANX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.11 vs -$0.14 consensus (+20.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 1, 2026
vs Industry
How GANX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related